Isryl-M 4 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 4 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances insulin secretion from pancreatic beta cells, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The synergistic action of these two agents helps in achieving optimal blood glucose regulation in patients inadequately controlled by diet and exercise alone. Isryl-M 4 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. Patients should be advised to adhere strictly to prescribed dosing and report any unusual symptoms promptly to their healthcare provider.